Profile cover photo
Profile photo
WEP Clinical
About
Posts

Post has attachment

FDA Commissioner explains how agency will implement provisions of the 21st Century Cures Act and improve drug access for cancer patients
http://www.raps.org/Regulatory-Focus/News/2017/11/30/28956/Cures-Act-Implementation-Gottlieb-Says-Faster-Cancer-Drug-Approvals-Coming-for-Secondary-Indications/

Post has attachment

Post has attachment
Richard Klein, who worked for the FDA for over 40 years, is trying to dispel some misconceptions around expanded access
http://www.hcanews.com/news/dispelling-the-myths-and-misconceptions-around-expanded-access

Post has attachment
The UK NHS has launched a website to help educate the public on biosimilar drugs. Check out our blog to learn more
http://www.wepclinical.com/uk-nhs-launches-website-educate-public-biosimilars/

Post has attachment
Some industry experts recommend we forget Right to Try and focus on improving existing infrastructure instead
http://www.hcanews.com/news/experts-express-concern-about-right-to-try-offer-alternatives

Lawmakers have introduced a new bill aimed at reducing drug waste in the US. Find out more on our blog
http://www.wepclinical.com/new-bill-aims-tackle-drug-waste-us/

Post has attachment
Should biosimilar drugs being developed for certain cancers and rare diseases require clinical trials?
http://www.appliedclinicaltrialsonline.com/do-biosimilars-require-clinical-trials

Post has attachment
FDA has announced it will expand which abbreviated new drug applications (ANDA) see priority reviews. Learn more on our blog
http://www.wepclinical.com/fda-announces-another-strategy-spur-generic-drug-development/

Post has attachment
Industry experts believe pharma and healthcare providers should work together to improve drug access and drive down prices
http://www.modernhealthcare.com/article/20171114/NEWS/171119949
Wait while more posts are being loaded